ALK-Abelló A/S (AKBLF)
USD 21.35
(-4.47%)
USD 21.35
(-4.47%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.03 Billion DKK | 8.74% |
| 2022 | 2.79 Billion DKK | 16.49% |
| 2021 | 2.39 Billion DKK | 18.15% |
| 2020 | 2.02 Billion DKK | 7.19% |
| 2019 | 1.89 Billion DKK | 15.86% |
| 2018 | 1.63 Billion DKK | -0.55% |
| 2017 | 1.64 Billion DKK | -18.35% |
| 2016 | 2.01 Billion DKK | 16.04% |
| 2015 | 1.73 Billion DKK | 2.12% |
| 2014 | 1.69 Billion DKK | 9.7% |
| 2013 | 1.54 Billion DKK | -8.84% |
| 2012 | 1.69 Billion DKK | -2.3% |
| 2011 | 1.73 Billion DKK | 16.81% |
| 2010 | 1.48 Billion DKK | 10.31% |
| 2009 | 1.34 Billion DKK | 7.24% |
| 2008 | 1.25 Billion DKK | 9.02% |
| 2007 | 1.15 Billion DKK | 16.23% |
| 2006 | 992 Million DKK | 23.38% |
| 2005 | 804 Million DKK | 0.0% |
| 2004 | - DKK | 0.0% |
| 2003 | - DKK | 0.0% |
| 2002 | - DKK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 867 Million DKK | -2.47% |
| 2024 Q1 | 889 Million DKK | 5.33% |
| 2023 Q3 | 685 Million DKK | -3.11% |
| 2023 Q2 | 707 Million DKK | -11.51% |
| 2023 Q1 | 799 Million DKK | 3.63% |
| 2023 FY | 3.03 Billion DKK | 8.74% |
| 2023 Q4 | 844 Million DKK | 23.21% |
| 2022 FY | 2.79 Billion DKK | 16.49% |
| 2022 Q3 | 640 Million DKK | -0.16% |
| 2022 Q1 | 739 Million DKK | 5.42% |
| 2022 Q2 | 641 Million DKK | -13.26% |
| 2022 Q4 | 771 Million DKK | 20.47% |
| 2021 Q3 | 559 Million DKK | 10.47% |
| 2021 FY | 2.39 Billion DKK | 18.15% |
| 2021 Q4 | 701 Million DKK | 25.4% |
| 2021 Q2 | 506 Million DKK | -19.68% |
| 2021 Q1 | 630 Million DKK | 8.81% |
| 2020 Q3 | 428 Million DKK | -1.83% |
| 2020 FY | 2.02 Billion DKK | 7.19% |
| 2020 Q1 | 585 Million DKK | 13.59% |
| 2020 Q2 | 436 Million DKK | -25.47% |
| 2020 Q4 | 579 Million DKK | 35.28% |
| 2019 FY | 1.89 Billion DKK | 15.86% |
| 2019 Q3 | 446 Million DKK | 11.78% |
| 2019 Q4 | 515 Million DKK | 15.47% |
| 2019 Q2 | 399 Million DKK | -25.0% |
| 2019 Q1 | 532 Million DKK | 22.58% |
| 2018 Q1 | 440 Million DKK | 17.02% |
| 2018 FY | 1.63 Billion DKK | -0.55% |
| 2018 Q3 | 384 Million DKK | -0.52% |
| 2018 Q2 | 386 Million DKK | -12.27% |
| 2018 Q4 | 434 Million DKK | 13.02% |
| 2017 FY | 1.64 Billion DKK | -18.35% |
| 2017 Q4 | 376 Million DKK | -2.08% |
| 2017 Q3 | 384 Million DKK | -2.29% |
| 2017 Q2 | 393 Million DKK | -19.63% |
| 2017 Q1 | 489 Million DKK | -0.41% |
| 2016 Q2 | 506 Million DKK | -15.95% |
| 2016 Q4 | 491 Million DKK | 19.17% |
| 2016 Q3 | 412 Million DKK | -18.58% |
| 2016 FY | 2.01 Billion DKK | 16.04% |
| 2016 Q1 | 602 Million DKK | 24.38% |
| 2015 Q4 | 484 Million DKK | 4.99% |
| 2015 Q1 | 440 Million DKK | 3.53% |
| 2015 Q2 | 348 Million DKK | -20.91% |
| 2015 FY | 1.73 Billion DKK | 2.12% |
| 2015 Q3 | 461 Million DKK | 32.47% |
| 2014 Q4 | 425 Million DKK | 25.74% |
| 2014 FY | 1.69 Billion DKK | 9.7% |
| 2014 Q3 | 338 Million DKK | -21.21% |
| 2014 Q2 | 429 Million DKK | -15.05% |
| 2014 Q1 | 505 Million DKK | 25.0% |
| 2013 Q2 | 351 Million DKK | -21.3% |
| 2013 FY | 1.54 Billion DKK | -8.84% |
| 2013 Q3 | 346 Million DKK | -1.42% |
| 2013 Q1 | 446 Million DKK | 0.0% |
| 2013 Q4 | 404 Million DKK | 16.76% |
| 2012 Q3 | 454 Million DKK | 28.98% |
| 2012 Q2 | 352 Million DKK | -20.9% |
| 2012 Q1 | 445 Million DKK | 8.01% |
| 2012 Q4 | 446 Million DKK | -1.76% |
| 2012 FY | 1.69 Billion DKK | -2.3% |
| 2011 Q4 | 412 Million DKK | 18.73% |
| 2011 Q2 | 324 Million DKK | -25.17% |
| 2011 Q3 | 347 Million DKK | 7.1% |
| 2011 Q1 | 433 Million DKK | -17.05% |
| 2011 FY | 1.73 Billion DKK | 16.81% |
| 2010 FY | 1.48 Billion DKK | 10.31% |
| 2010 Q3 | 346 Million DKK | 6.79% |
| 2010 Q1 | 403 Million DKK | 46.55% |
| 2010 Q4 | 522 Million DKK | 50.87% |
| 2010 Q2 | 324 Million DKK | -19.6% |
| 2009 FY | 1.34 Billion DKK | 7.24% |
| 2009 Q4 | 275 Million DKK | -15.12% |
| 2009 Q3 | 324 Million DKK | 14.89% |
| 2009 Q2 | 282 Million DKK | -21.45% |
| 2009 Q1 | 359 Million DKK | 0.0% |
| 2008 FY | 1.25 Billion DKK | 9.02% |
| 2007 FY | 1.15 Billion DKK | 16.23% |
| 2006 FY | 992 Million DKK | 23.38% |
| 2005 FY | 804 Million DKK | 0.0% |
| 2004 FY | - DKK | 0.0% |
| 2003 FY | - DKK | 0.0% |
| 2002 FY | - DKK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioxytran, Inc. | -8285.00 USD | 36632568.316% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -20134.682% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -30888.36% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -4617414.606% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -25826.875% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -2448.117% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 8887362.079% |
| Marizyme, Inc. | 457.7 Thousand USD | -662995.202% |
| Genus plc | 178.7 Million USD | -1598.377% |
| Pharming Group N.V. | 220.1 Million USD | -1278.894% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -4877282.445% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -739846.119% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 27591009.091% |
| ContraFect Corporation | -154 Thousand USD | 1970879.221% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -3953730.721% |
| IMV Inc. | -962.29 Thousand USD | 315490.866% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 783323.785% |
| ONE Bio Corp. | 20.12 Million USD | -14980.415% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -7437.564% |
| Mesoblast Limited | -35.16 Million USD | 8730.005% |
| MultiCell Technologies, Inc. | 49.32 USD | -6153690086.537% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -10641.462% |
| Genscript Biotech Corporation | 409.55 Million USD | -641.052% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -97840003.159% |
| Biomind Labs Inc. | -15.42 Thousand USD | 19677226.556% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 265961.461% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -4335614.286% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 2442736.277% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 61288468.336% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 6070100.0% |
| Arch Therapeutics, Inc. | -2439.00 USD | 124436344.362% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -2160042.349% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -6206443.967% |
| Q BioMed Inc. | -8988.00 USD | 33767345.216% |
| GB Sciences, Inc. | -624.00 USD | 486378305.128% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 3528021.142% |
| CSL Limited | 7.56 Billion USD | 59.86% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -6742.086% |
| Enzolytics Inc. | 30.7 Thousand USD | -9883318.002% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -629002.901% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 3112441.691% |
| argenx SE | 1.1 Billion USD | -173.798% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 11864.478% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 1459134715.385% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 589981.635% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 34270651.039% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -491490.323% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 3619701.903% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -307092.142% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -31478.4% |
| Kadimastem Ltd | -630.13 Thousand USD | 481740.53% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | -19576.046% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 25644375.454% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 6289082.366% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -1718862.392% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -1718862.392% |
| Affymax, Inc. | 1.35 Million USD | -223531.555% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -65763.715% |
| CytoDyn Inc. | -29 Thousand USD | 10465617.241% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -674280.004% |
| SYBLEU INC | 11.69 Thousand USD | -25948942.408% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 950000.941% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 813772.922% |
| Neutra Corp. | 14.33 Thousand USD | -21171856.749% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 3701319.512% |
| PureTech Health plc | -1.6 Million USD | 189432.502% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 303225.337% |
| IXICO plc | 3.27 Million USD | -92713.456% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 437419.885% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 169558.403% |
| CSL Limited | 7.7 Billion USD | 60.61% |
| Cellectis S.A. | 18 Thousand USD | -16861011.111% |